AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$AGMB

Knotnerus Tim Jasper purchased $94K of AGMB

Knotnerus Tim Jasper (Chief Executive Officer) purchased 11,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $8.58 ($8.48–$8.70) across 2 trades over 2026-10-05 to 2026-10-06.

Original reporting
SEC EDGAR · Knotnerus Tim Jasper
Published Oct 7, 2026, 12:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 12:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AGMB
Neutral
medium confidence
Mentioned
$AGMB
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AGMBNeutralLow
01

Why it matters

The CEO's modest buy may be viewed as a positive sign but is unlikely to move the stock significantly.

02

Market read

Limited relevance; primarily of interest to shareholders and short‑term traders monitoring insider activity.

03

What to watch

Potential upcoming clinical data or financing needs not disclosed in the filing.

Relevance 4/10Novelty 3/10Timing: immediate (today)

Background

Form 4 filings disclose insider transactions; investors watch for signals of confidence.

Company-level read

Ticker impact

$AGMBNeutralMedium confidence
Context

CEO Tim Jasper bought 11,000 shares for $94,380, increasing his stake to 21,823 shares.

Expected impact

likely slight upward pressure as market prices in insider confidence

Evidence & confidence

The purchase is under $100k, typical for routine buybacks; impact on price is limited.

Market effects

Sector

Minimal; biotech sector not broadly affected by a small insider purchase.

Regional

None beyond the company's own stock.

Global

Low; no wider market impact.

Counterpoint

What could challenge this read

The purchase could be routine compensation rather than a strong bullish signal.

Key entities

  • Executive
    Tim Jasper

    Chief Executive Officer of AgomAb Therapeutics NV

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AGMB insider trading history →

Related articles

OCT 2
$AGMBMedAI 8/10

H.C. Wainwright reiterates Agomab stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $35 price target on Agomab Therapeutics (AGMB) after positive Phase 2a STENOVA trial data. The stock is near its 52-week low, down 18% in a week. Analysts' price targets range from $28 to $60. Agomab has no debt and holds more cash, providing financial flexibility. Piper Sandler and B. Riley also initiated coverage with positive ratings and targets of $60 and $34, respectively.

investing.com2 min
OCT 1
$AGMBMedAI 8/10

Why is Agomab Therapeutics stock sliding today?

Agomab Therapeutics (AGMB) shares fell 6.1% despite positive 60-week trial data for ontunisertib, showing sustained disease control in Crohn’s patients. The decline followed a pre-market gain and a downgrade to 'Sell' by Wall Street Zen. The stock's 52-week range is $8.75 to $17.82, with a current price of $10.43, below the consensus target.

investing.com2 min
OCT 1
$AGMBHighAI 8/10

Agomab stock jumps on positive trial data

Agomab Therapeutics (NASDAQ:AGMB) shares rose 6.3% premarket after positive trial data for ontunisertib in Crohn's disease. The STENOVA extension study showed favorable safety, low event rates, and sustained disease control. 97% of patients were in remission at Week 48. The company plans a Phase 2b study. Ontunisertib has FDA Fast Track Designation.

investing.com2 min
AUG 13
$AGMBMed

AG Mortgage Bank's N3.97bn CP Fully Subscribed

AG Mortgage Bank Plc said its Series 2 and 3 commercial paper issuance under a N5bn programme was fully subscribed, raising N3.97bn. The notes were issued June 10 to June 18 with tenors of 270 and 364 days and gross implied yields of 22.5% to 24%. FSDH Capital led arrangers. For FY2025, interest income rose 28.1% to N3.65bn and profit after tax doubled to N1.05bn.

punchng.com4 min